ATE365158T1 - Pyrimidincarbonsäurederivate - Google Patents

Pyrimidincarbonsäurederivate

Info

Publication number
ATE365158T1
ATE365158T1 AT00922876T AT00922876T ATE365158T1 AT E365158 T1 ATE365158 T1 AT E365158T1 AT 00922876 T AT00922876 T AT 00922876T AT 00922876 T AT00922876 T AT 00922876T AT E365158 T1 ATE365158 T1 AT E365158T1
Authority
AT
Austria
Prior art keywords
group
hydrogen atom
alkyl group
carboxylic acid
acid derivatives
Prior art date
Application number
AT00922876T
Other languages
English (en)
Inventor
Hiroyuki Kagechika
Original Assignee
Inst Med Molecular Design Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Med Molecular Design Inc filed Critical Inst Med Molecular Design Inc
Application granted granted Critical
Publication of ATE365158T1 publication Critical patent/ATE365158T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00922876T 1999-04-28 2000-04-26 Pyrimidincarbonsäurederivate ATE365158T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12159299 1999-04-28

Publications (1)

Publication Number Publication Date
ATE365158T1 true ATE365158T1 (de) 2007-07-15

Family

ID=14815077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922876T ATE365158T1 (de) 1999-04-28 2000-04-26 Pyrimidincarbonsäurederivate

Country Status (7)

Country Link
US (1) US6869959B1 (de)
EP (1) EP1180520B1 (de)
JP (1) JP4693247B2 (de)
AT (1) ATE365158T1 (de)
AU (1) AU4314000A (de)
DE (1) DE60035271D1 (de)
WO (1) WO2000066595A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200302728A (en) 2002-02-01 2003-08-16 Novartis Ag Substituted amines as IgE inhibitors
HK1079993B (zh) 2002-04-22 2010-03-19 财团法人乙卯研究所 用於血管性疾病治疗的药物
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び／又は治療のための医薬
JPWO2006043515A1 (ja) * 2004-10-22 2008-05-22 杏林製薬株式会社 ピリミジン−５−カルボン酸誘導体
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
ES2544482T3 (es) 2007-02-27 2015-08-31 National University Corporation Okayama University Compuesto rexinoide que tiene un grupo alcoxi
JP5211322B2 (ja) * 2008-03-07 2013-06-12 国立医薬品食品衛生研究所長 ピリミジン−５−カルボン酸誘導体の抗肥満剤としての新規用途
WO2011055843A1 (ja) * 2009-11-09 2011-05-12 国立大学法人 岡山大学 レチノイド化合物
EP2755942A2 (de) * 2011-09-15 2014-07-23 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Therapeutische verbindungen
RU2721283C2 (ru) * 2014-01-14 2020-05-18 Конекшис Лайф Сайенсиз Пвт. Лтд. Замещенные бициклические гетероарильные соединения в качестве агонистов rxr
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
WO2015130973A1 (en) * 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064259A (en) 1963-12-19 1967-04-05 Union Pharma Scient Appl New derivatives of 2-anilino-nicotinic acid and process for their preparation
US3466373A (en) 1963-12-19 1969-09-09 Lab U P S A Analgesic and anti-inflammatory composition consisting essentially of 2-(2,3-xylylamino)-nicotinic acid
DE1670537A1 (de) 1966-11-09 1970-10-29 Degussa Verfahren zur Herstellung neuer substituierter Aminopyrimidine
US4207330A (en) 1978-07-03 1980-06-10 The Dow Chemical Company Method for treating hyperglycemia in mammals using arylamino benzoic acids
US4143151A (en) * 1978-07-03 1979-03-06 The Dow Chemical Company Method for treating hyperglycemia in mammals using arylamino benzoic acids
JPS60100559A (ja) * 1983-11-05 1985-06-04 Morishita Seiyaku Kk ２−アニリノ−１，６−ジヒドロ−６−オキソ−５−ピリミジンカルボン酸誘導体，その製法及び該化合物を含有する抗アレルギ−剤
JPS6122047A (ja) 1984-07-07 1986-01-30 Koichi Shiyudo 安息香酸誘導体
JPS6176440A (ja) 1984-09-19 1986-04-18 Koichi Shiyudo 安息香酸誘導体
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
FR2581063B1 (fr) * 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
JPS62123180A (ja) * 1985-11-21 1987-06-04 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
US4788195A (en) 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4876252A (en) 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4868183A (en) 1986-07-21 1989-09-19 Otsuka Pharmaceutical Factory, Inc. N-pyrazinyl substituted P-aminophenols
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH03204813A (ja) * 1989-09-27 1991-09-06 Otsuka Pharmaceut Factory Inc 抗活性酸素剤
US5119033A (en) 1989-09-29 1992-06-02 Rosemount Inc. Vernier voltage-to-digital converter with a storage capacitance selectable in magnitude
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
US6162815A (en) 1994-04-26 2000-12-19 Centre International De Recherches Dermatologiques Galderma RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof
FR2719043B1 (fr) 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bicycliques-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
TW420667B (en) 1995-09-21 2001-02-01 Inst Med Molecular Design Inc Benzoazipine compounds for enhancing the action of a retinoid
JPH09100270A (ja) 1995-10-03 1997-04-15 Koichi Shudo レチノイドアンタゴニスト
CA2233888A1 (en) 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
AU7598596A (en) 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
KR100485642B1 (ko) 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
JP2000511558A (ja) 1996-06-21 2000-09-05 アラーガン・セイルズ・インコーポレイテッド レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
JPH10338658A (ja) 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US6093838A (en) 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity

Also Published As

Publication number Publication date
EP1180520A1 (de) 2002-02-20
WO2000066595A1 (en) 2000-11-09
AU4314000A (en) 2000-11-17
EP1180520A4 (de) 2002-06-05
EP1180520B1 (de) 2007-06-20
DE60035271D1 (en) 2007-08-02
US6869959B1 (en) 2005-03-22
JP4693247B2 (ja) 2011-06-01

Similar Documents

Publication Publication Date Title
ATE365158T1 (de) Pyrimidincarbonsäurederivate
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
DK1117648T3 (da) Tetrahydroquinolinderivater med selektiv virkning for retinoid X receptorer
DE69929877D1 (de) BENZOCHINONDERIVATE ENTHALTENDE HEMMER VON NF-kB
ATE316967T1 (de) Zyklische amidderivate die cathepsin k hemmen
ATE19074T1 (de) Octahydronaphthalin-derivate und ihre herstellung.
FI952101A0 (fi) Merkaptanfoerening
ATE358484T1 (de) Antidiabetische medikamente
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
DE69223827D1 (de) Glycyrrheticsäurederivate
BR9913385A (pt) Composição antimicrobiana
NO20014119L (no) Medikament inneholdende et sulfopyranosylacylglycerolderivat
ZA200106514B (en) Heterocyclic compounds intermediates thereof and elastase inhibitors.
MY141488A (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
ATE194982T1 (de) Benzoxazepin-derivate als cholinesterase- inhibitoren
WO2000044722A8 (en) Chondrongenesis promotors and indolin-2-one derivatives
ATE122669T1 (de) Zearalanol-derivate mit anabolytischer wirkung.
EP1293200A4 (de) Mittel die die aktivität des nervenwachstumsfaktors potenzieren
DE69123757D1 (de) Epoxysuccinamidsäurederivat
ES2059364T3 (es) Compuestos macrolidos.
WO2000027378A3 (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
ES2195016T3 (es) Medicamento contra la trombocitopenia.
FI821038L (fi) Morfoliner
WO1997029096A1 (en) Micacocidin derivatives
EP1219608A4 (de) Pyrimidinderivate, verfahren zur herstellung der derivate und sie als aktiven bestandteil enthaltende medikamente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties